AOA Diagnostics, a Denver-based startup, is pioneering a novel blood test designed for the early detection of ovarian cancer. This initiative addresses the critical lack of effective screening tools, which currently leads to approximately 80% of ovarian cancer cases being diagnosed at advanced stages, significantly reducing survival rates.
Unmet Need in Ovarian Cancer Detection
Ovarian cancer is often termed a "silent killer" due to its subtle and easily overlooked early symptoms, frequently misdiagnosed as irritable bowel syndrome (IBS) or other common ailments. The absence of reliable early detection methods results in late-stage diagnoses, where treatment options are limited and less effective. Ingrid Kolstoe, a stage 4 ovarian cancer patient, emphasized the importance of early detection, stating, "to be able to catch cancer in its earliest stages provides the best hope for anyone."
AOA Diagnostics' Innovative Approach
AOA Diagnostics, founded by women, is focused on translating research into clinical applications. CEO and Co-Founder Oriana Papin-Zoghbi explained that much cancer detection research remains confined to academic institutions, hindering its practical implementation. AOA's mission is to bridge this gap and transform women's health by developing accessible and effective diagnostic tools. The initial focus is on ovarian cancer due to the significant unmet need and promising early research results. However, the long-term goal is to expand the technology to detect other cancers affecting women.
Colorado as an Innovation Hub
Despite starting remotely during the COVID-19 pandemic, AOA Diagnostics secured substantial funding and established a state-of-the-art lab in Colorado. Papin-Zoghbi highlighted Colorado's burgeoning life sciences sector and the availability of skilled talent as key factors in the company's decision to locate there. AOA is actively collaborating with UCHealth and other academic institutions in Colorado, positioning the state at the forefront of innovative cancer diagnostics.
Clinical Study and Future Prospects
AOA Diagnostics is currently conducting a clinical study to validate its early detection tool. The study aims to demonstrate the test's accuracy and effectiveness in identifying ovarian cancer at its earliest stages. The development of this blood test offers hope for a future where ovarian cancer can be detected and treated more effectively, improving outcomes for women worldwide. Those interested in participating in the clinical study can visit overt-trial.com for more information.
